	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	153.18	125.26	122.32	220.58	295.02	302.89	279.38	227.58	282.35	380.14	451.07	372.25	368.59	318.23	232.13	232.44
Cost of Operating Revenue	126.41	116.51	82.31	159.94	206.72	202.49	169.93	160.40	203.34	260.61	343.89	291.17	290.05	214.32	175.10	168.28
Gross Profit	26.77	8.75	40.01	60.64	88.30	100.40	109.45	67.18	79.02	119.53	107.18	81.09	78.55	103.91	57.03	64.16
Gross Margin	17.5	7.0	32.7	27.5	29.9	33.1	39.2	29.5	28.0	31.4	23.8	21.8	21.3	32.7	24.6	27.6
Total Operating Expenses	142.73	133.61	116.92	204.38	261.74	261.20	239.10	224.93	266.82	335.99	412.26	357.72	365.78	298.67	265.26	259.26
Operating Profit	10.45	-8.35	5.40	16.20	33.28	41.69	40.28	2.65	15.53	44.15	38.81	14.53	2.81	19.56	-33.13	-26.82
Operating Margin	6.8	-6.7	4.4	7.3	11.3	13.8	14.4	1.2	5.5	11.6	8.6	3.9	0.8	6.1	-14.3	-11.5
Financing Income/(Expense) - Net	-10.15	-10.00	-9.74	-10.28	-9.29	-10.04	-11.78	-8.65	-10.40	-9.33	-11.07	-12.45	-13.82	-14.87	-16.21	-15.84
Profit before Taxes	1.14	-16.80	-3.91	6.01	24.02	31.18	29.35	-5.74	6.25	39.52	27.73	2.21	-11.06	4.79	-48.57	-42.32
Income Taxes	0.50	-5.00	-0.87	-0.13	7.98	8.91	9.46	2.29	-2.00	11.55	8.08	0.94	-2.01	-1.93	-4.17	-4.08
Profit after Tax	0.63	-11.80	-3.04	6.14	16.03	22.28	19.89	-8.03	8.25	27.97	19.66	1.27	-9.05	6.72	-44.40	-38.24
PAT Margin	0.4	-9.4	-2.5	2.8	5.4	7.4	7.1	-3.5	2.9	7.4	4.4	0.3	-2.5	2.1	-19.1	-16.5
EPS - Basic - ex Extraordinary Items	0.48	-8.95	-2.31	4.66	11.15	14.07	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72	4.25	-28.05	-24.16
EPS - Diluted - ex Extraordinary Items	0.48	-8.95	-2.31	4.66	10.13	14.07	12.57	-5.07	5.21	17.67	12.42	0.80	-5.72	4.25	-28.05	-24.16
EBIT	10.45	-8.35	5.40	16.20	33.28	41.69	40.28	2.65	15.53	44.15	38.81	14.53	2.81	19.56	-33.13	-26.82
EBITDA	14.19	-4.41	9.41	20.36	37.69	46.70	46.85	9.73	23.75	53.33	49.05	25.52	17.45	36.17	-14.90	-8.99
EBITDA Margin	9.3	-3.5	7.7	9.2	12.8	15.4	16.8	4.3	8.4	14.0	10.9	6.9	4.7	11.4	-6.4	-3.9

Balance Sheet

Abridged

Understanding Balance Sheet

Mangalam Drugs And Organics Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	IR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	62.85	57.43	71.41	116.04	99.65	95.78	122.84	105.04	119.17	133.92	182.47	206.58	199.78	198.98	155.71
Long-Term Investments	-	-	-	-	-	-	0.24	0.24	0.22	0.22	0.00	0.00	0.03	0.00	0.00
Property Plant & Equipment - Net	56.99	55.13	53.38	52.95	59.12	92.51	101.23	103.21	96.17	114.21	126.79	133.55	126.52	133.60	125.99
Total Non-Current Assets	59.10	57.34	54.03	53.86	60.11	93.72	103.95	106.32	111.49	130.19	145.96	153.04	157.36	167.44	159.26
Total Assets	121.95	114.78	125.44	169.90	159.76	189.50	226.79	211.35	230.67	264.11	328.43	359.63	357.14	366.42	314.97
Total Current Liabilities	55.47	42.83	61.43	99.43	72.87	77.76	99.84	90.81	109.47	109.08	130.11	165.36	180.95	191.60	196.58
Long Term Debt	21.96	44.24	40.20	39.40	16.92	16.85	11.15	10.54	4.97	10.07	34.26	25.51	18.49	11.75	8.56
Total Non-Current Liabilities	28.41	45.69	40.79	41.10	25.37	26.03	23.18	24.88	17.26	24.25	47.75	42.32	33.85	25.84	15.33
Total Liabilities	83.88	88.52	102.22	140.53	98.24	103.79	123.02	115.69	126.73	133.32	177.86	207.67	214.80	217.44	211.91
Total Shareholders' Equity	38.06	26.26	23.22	29.36	61.52	85.72	103.77	95.66	103.94	130.79	150.56	151.96	142.35	148.98	103.06
Total Equity	38.06	26.26	23.22	29.36	61.52	85.72	103.77	95.66	103.94	130.79	150.56	151.96	142.35	148.98	103.06
Total Liabilities & Equity	121.95	114.78	125.44	169.90	159.76	189.50	226.79	211.35	230.67	264.11	328.43	359.63	357.14	366.42	314.97

Cash Flow

Abridged

Understanding Cash Flow Statement

Mangalam Drugs And Organics Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	4.21	-13.01	0.04	10.17	24.65	31.29	29.65	1.85	14.50	38.16	30.14	13.41	2.65	20.37	-32.35
Working Capital - Increase/(Decrease)	-7.31	2.36	-2.29	-6.48	-12.11	1.49	-16.81	11.21	5.64	-19.94	-15.59	13.36	-4.39	7.29	20.32
Net CF from Operating Activities	-3.10	-10.65	-2.25	3.69	12.54	32.78	12.84	13.07	20.14	18.22	14.55	26.77	-1.75	27.66	-12.03
Capital Expenditures - Net	6.26	2.04	2.28	3.80	10.90	39.46	15.98	9.28	6.89	31.29	27.53	22.17	17.88	19.47	11.73
Net CF from Investing Activities	-6.26	-2.08	-2.27	-3.86	-10.90	-39.47	-15.98	-9.28	-6.87	-31.29	-27.33	-22.17	-17.91	-19.47	-11.73
Dividends Paid - Cash - Total	-	-	-	-	-	-	0.79	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	16.28	0.94	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	9.69	11.80	4.54	0.74	-18.10	5.87	3.73	-2.79	-13.07	12.02	14.14	-3.87	19.62	-6.78	21.87
Net Cash Flow from Financing Activities	9.69	11.80	4.54	0.74	-1.82	6.82	2.94	-2.79	-13.07	12.02	14.14	-3.87	19.62	-6.78	21.87
Free Cash Flow to Equity	0.33	-0.90	0.01	0.64	-16.47	-0.81	0.58	1.00	0.18	-1.04	1.16	0.73	-0.01	1.41	-1.89
Free Operating CF net dividend	-9.37	-12.76	-4.55	-0.12	1.45	-6.75	-3.94	3.73	13.21	-13.21	-13.12	-1.14	-19.66	7.46	-23.93
Free Operating CF	-9.37	-12.76	-4.55	-0.12	1.45	-6.75	-3.15	3.73	13.21	-13.21	-13.12	-1.14	-19.66	7.46	-23.93

Business Segment Analysis

FY End:

Mar 25

Mangalam Drugs And Organics Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing of Bulk Drugs (100.0%)₹ 20.20 Cr

Revenue / Sales

Manufacturing of Bulk Drugs (100.0%)₹ 318.23 Cr

Assets

Manufacturing of Bulk Drugs (100.0%)₹ 366.42 Cr

Operating Income

Manufacturing of Bulk Drugs (100.0%)₹ 19.56 Cr

Regional Segment Analysis

FY End:

Mar 12

Mangalam Drugs And Organics Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (93.2%)₹ 142.81 CrExport (6.8%)₹ 10.37 Cr

Historical Segment Analysis

Track how Mangalam Drugs And Organics Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2024 Mar 31	2025 Mar 31
	2024 Mar 31	2025 Mar 31
Manufacturing of Bulk Drugs	18	20

Frequently Asked Questions

What is the revenue of Mangalam Drugs And Organics Ltd.?

The latest trailing twelve month revenue of Mangalam Drugs And Organics Ltd. is ₹ 232.44 Cr, reflecting a 1-year growth of -22.27% and a 3-year CAGR of -12.77%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Mangalam Drugs And Organics Ltd.?

The latest trailing twelve month net profit (PAT) of Mangalam Drugs And Organics Ltd. is ₹ -39.13 Cr, with a 3-year earnings CAGR of -50.29%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Mangalam Drugs And Organics Ltd.?

The trailing twelve month EBITDA of Mangalam Drugs And Organics Ltd. is approximately ₹ -26.82 Cr (based on an operating margin of -11.54%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Mangalam Drugs And Organics Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Mangalam Drugs And Organics Ltd. is -24.16. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Mangalam Drugs And Organics Ltd.?

The debt-to-equity ratio of Mangalam Drugs And Organics Ltd. stands at 1.02. The interest coverage ratio is -1.69x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Mangalam Drugs And Organics Ltd.?

The estimated book value per share of Mangalam Drugs And Organics Ltd. is 65.11 (derived from a P/B ratio of 0.43 and market price of ₹ 27.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Mangalam Drugs And Organics Ltd.?

The trailing twelve month operating cash flow of Mangalam Drugs And Organics Ltd. is ₹ -12.03 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Mangalam Drugs And Organics Ltd. report consolidated or standalone financials?

Mangalam Drugs And Organics Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.